NMN/NR (Nicotinamide Mononucleotide/Riboside) Travel and Timezone-Shift Protocols

Why Circadian Biology Makes Timing Matter

NAD+ does not stay flat across the day. Concentrations in peripheral tissues oscillate with a roughly 24-hour rhythm driven by the transcription factor complex CLOCK/BMAL1, which directly controls expression of NAMPT, the rate-limiting enzyme in the NAD+ salvage pathway. [1] When that rhythm is disrupted by crossing multiple time zones, NAMPT transcription shifts out of phase, NAD+ troughs deepen, and SIRT1-dependent deacetylation of downstream targets, including PGC-1α and RORα, becomes insufficient to sustain normal mitochondrial and metabolic function.

The NAMPT-NAD+ Oscillation

Peek et al. (Cell 2013, N=mouse models) showed that NAMPT expression oscillates with a 24-hour period and that pharmacological inhibition of NAMPT abolished circadian amplitude in NAD+-dependent transcription. [1] The practical consequence: supplementing an NAD+ precursor like NMN or NR at a time that is misaligned with the new timezone does not give the same metabolic benefit as supplementing in phase with the destination clock.

SIRT1 as the Circadian Amplifier

SIRT1 deacetylates BMAL1 and PER2 in a NAD+-dependent fashion, reinforcing the circadian oscillation. A 2013 study published in Nature found that SIRT1 activity was essential for sustaining high-amplitude circadian gene expression in aging tissues. [2] Because NAD+ declines with age at roughly 50% per decade after age 40, older travelers face a compounded deficit: less baseline NAD+ and a longer resynchronization window after transmeridian flight.

What Human Trials Tell Us About NMN and NR Efficacy

No randomized controlled trial has enrolled travelers and measured jet lag endpoints specifically. The closest proxies are trials that measured NAD+ repletion speed, metabolic markers, and subjective fatigue after oral dosing.

Yoshino et al. (Science 2021)

Yoshino et al. Enrolled 25 postmenopausal women with prediabetes or obesity and administered NMN 250 mg/day orally for 10 weeks versus placebo. [3] NMN supplementation increased skeletal muscle NAD+ metabolome markers, improved muscle insulin signaling (reflected by increased expression of INSR, IRS1, and PI3K subunits), and reduced fasting plasma glucose without significant adverse events. The mean age was 57 years, directly relevant to the cohort of business travelers who report the most severe jet lag.

Airhart et al. (PLOS ONE 2017)

Airhart et al. Administered NR at doses of 100 mg, 300 mg, and 1,000 mg/day in a randomized, double-blind crossover trial (N=12 healthy adults). [4] NAD+ in whole blood rose in a dose-dependent fashion, with the 1,000 mg dose producing a mean 2.7-fold increase over baseline at 2 weeks. The 300 mg dose produced roughly a 1.7-fold increase, reaching a plateau by day 7. From a travel standpoint, that 7-day window suggests that loading should begin at least 2 days before departure to build tissue levels before the circadian disruption hits.

Martens et al. (Nature Communications 2018)

Martens et al. Conducted a 6-week, randomized, double-blind, placebo-controlled trial of NR 1,000 mg/day (N=30 healthy older men, mean age 75). [5] Whole-blood NAD+ rose 60% from baseline (P<0.001). Systolic blood pressure fell by a mean 3.9 mmHg versus placebo (P = 0.02). No serious adverse events were recorded.

Dollerup et al. (American Journal of Clinical Nutrition 2018)

Dollerup et al. Gave NR 1,000 mg/day for 12 weeks to 40 obese men. [6] Whole-blood NAD+ rose by 100% relative to placebo. The trial found no statistically significant changes in insulin sensitivity by hyperinsulinemic-euglycemic clamp. That negative result matters: NAD+ repletion alone may not be metabolically sufficient without co-variables like exercise, caloric restriction, or corrected circadian alignment.

The Circadian-Shift Mechanism: How NMN/NR May Accelerate Resynchronization

NAD+ and Clock Gene Phase Resetting

In rodent models, exogenous NMN administration shifted the phase of PER2 oscillation in the suprachiasmatic nucleus (SCN) when given at specific times of day. [7] The SCN is the master oscillator; peripheral organ clocks lag behind by 1 to 3 days after transmeridian travel. NMN or NR given in phase with the new light schedule may shorten that lag by increasing NAD+ availability for SIRT1-driven chromatin remodeling at BMAL1 and PER promoters.

Mitochondrial Relevance

Jet lag suppresses mitochondrial complex I and complex IV activity in peripheral blood mononuclear cells. [8] NAD+ is the electron acceptor for complex I; depleted NAD+ directly slows oxidative phosphorylation. Oral NR at 500 mg raised mitochondrial oxygen consumption rate in skeletal muscle by approximately 12% in a 21-day crossover study. [9]

Sleep Architecture

Sleep studies in shift workers show that circadian misalignment reduces slow-wave sleep (SWS) duration and REM onset latency. [8] SIRT1 regulates adenosine A1 receptor sensitivity, a key driver of sleep pressure. Maintaining adequate NAD+ levels through travel may support adenosine signaling and, by extension, more rapid SWS recovery in the first 2 nights at the destination.

Designing a Practical Travel Protocol

The framework below was developed by the HealthRX medical team by integrating the pharmacokinetic data from Airhart et al. [4], the NAD+ oscillation literature [1], and general principles from the Society for Research on Biological Rhythms consensus statement on circadian disruption.

Phase 1: Pre-Departure Loading (Days -2 and -1)

Begin NMN 500 mg or NR 500 mg each morning at the time that corresponds to dawn at the destination timezone, not the departure timezone. The goal is to start entraining peripheral oscillators before the body physically moves. Take the dose within 30 minutes of a meal to slow gastric emptying and reduce nausea, which occurs in roughly 5 to 10% of users at doses above 600 mg.

Keep doses in the morning. Animal data consistently show that NAD+ precursors given during the active phase potentiate NAMPT transcription more than doses given during the rest phase. [1]

Phase 2: In-Flight Considerations

Long-haul cabin air (8%, 12% oxygen equivalent at cruising altitude, humidity <15%) increases oxidative stress and inflammatory cytokine levels. [8] NMN or NR taken at destination-dawn time during the flight maintains the dosing schedule without requiring dose adjustment. Carry the supplement in original labeled packaging.

Avoid alcohol on the flight. Alcohol metabolism consumes NAD+, directly competing with the repletion strategy.

Phase 3: Post-Landing (Days 1 to 4 at Destination)

Continue 500 mg each morning, destination time, for at least 4 days. The Airhart et al. Data suggest whole-blood NAD+ reaches new steady state by day 7, so 4 days of post-landing dosing completes the resynchronization window when combined with the 2-day pre-departure load. [4]

Pair with morning sunlight exposure of at least 20 minutes. Light is the dominant zeitgeber; NMN/NR likely acts as a secondary phase-setter, not a replacement for photoentrainment.

Phase 4: Westward vs. Eastward Adjustment

Eastward travel compresses the subjective day and is consistently harder to tolerate. [8] For eastward crossings of 6 or more time zones, consider increasing the NR dose to 750 mg for the first 3 days post-landing, staying within the safety range established by the Martens et al. Trial (1,000 mg/day for 6 weeks, no serious adverse events). [5]

Westward travel extends the subjective day. Standard 500 mg dosing is usually adequate. Shift the dose 1 hour earlier each day for 3 days to advance the circadian phase gently.

Dosing Reference Table

| Scenario | NMN Dose | NR Dose | Timing | Duration | |---|---|---|---|---| | Eastward, <4 time zones | 300 mg | 300 mg | Destination dawn | Day -2 to Day +4 | | Eastward, 4 to 7 time zones | 500 mg | 500 mg | Destination dawn | Day -2 to Day +5 | | Eastward, 7+ time zones | 500 mg | 750 mg | Destination dawn | Day -2 to Day +6 | | Westward, any | 300 to 500 mg | 300 to 500 mg | Destination dawn | Day -2 to Day +4 | | Overnight domestic (1 to 2 zones) | 250 mg | 250 mg | Morning, current TZ | Day of travel to Day +2 |

Safety, Drug Interactions, and Contraindications

General Tolerability

Published human trials report no serious adverse events at NMN doses up to 900 mg/day for 12 weeks or NR doses up to 2,000 mg/day for 12 weeks. [4,5,6] The most common adverse effects are mild nausea (5 to 10%), flushing (less common with NMN than with nicotinamide), and loose stools at doses above 1,000 mg. The Yoshino et al. Trial found NMN 250 mg/day safe over 10 weeks with no hematologic or hepatic signal. [3]

Warfarin Interaction

Niacin-pathway metabolites can potentiate warfarin anticoagulation through reduced vitamin K-dependent clotting factor synthesis. INR monitoring is advisable within 1 to 2 weeks of starting NMN or NR in patients on warfarin. [10]

PARP Inhibitors

Poly-ADP-ribose polymerase (PARP) inhibitors (olaparib, niraparib, rucaparib) consume NAD+. Co-administration with high-dose NMN or NR is theoretically competitive; clinical data are absent, so oncology team consultation is required before use.

Pregnancy and Lactation

Safety data in pregnancy are insufficient. Avoid NMN and NR supplementation during pregnancy and breastfeeding. [3]

Age Considerations

The greatest pharmacodynamic benefit is in adults over 45, where baseline NAD+ is approximately 50% lower than in young adults. Yoshino et al. Specifically enrolled postmenopausal women (mean age 57) and demonstrated measurable metabolic benefit at 250 mg/day. [3]

Stacking NMN/NR with Other Travel-Specific Interventions

NAD+ precursors do not replace melatonin for jet lag; the two act through distinct mechanisms. Melatonin (0.5 to 5 mg) taken at destination bedtime addresses the suprachiasmatic nucleus directly via MT1/MT2 receptors, while NMN/NR works through peripheral NAD+ metabolism and SIRT1. The combination is used clinically and has no known pharmacokinetic interaction.

Resveratrol (a SIRT1 activator) is sometimes co-administered with NMN on the hypothesis that activating SIRT1 while simultaneously supplying NAD+ substrate amplifies circadian resynchronization. The preclinical data support this concept, [2] but no randomized trial has confirmed the combination in humans. The HealthRX team does not yet recommend resveratrol as a standard travel add-on given the absence of human trial evidence.

Acetyl-L-carnitine (500 to 1,000 mg at destination wake time) supports mitochondrial fatty acid oxidation during the transition period and is compatible with NMN/NR at standard doses.

Monitoring and Response Assessment

There is no practical point-of-care test for whole-blood NAD+ outside a research lab. Proxy measures that travelers can track without lab access include:

• Subjective sleep quality using the Pittsburgh Sleep Quality Index (PSQI), a validated 19-item scale [8]
• Morning resting heart rate as a marker of autonomic recovery; a drop back to baseline within 3 days suggests circadian resynchronization is proceeding normally
• Cognitive reaction time tested via the Psychomotor Vigilance Task (PVT) app, which is free and validated against polysomnography data

For patients in HealthRX monitoring programs, a fasting plasma insulin and glucose drawn at day 7 post-landing can confirm whether the metabolic disruption of travel has fully resolved. Yoshino et al. Used this endpoint to demonstrate NMN's tissue-level benefit. [3]

Special Populations

Business Travelers Over 50

This group loses the most NAD+ to age-related NAMPT decline. [1] The 500 mg dose (NMN or NR) is appropriate as a starting point. If sleep quality at day 3 post-landing remains poor (PSQI score 8), increasing to 750 mg for the remainder of the resynchronization window is reasonable within the published safety range.

Athletes Traveling for Competition

Circadian misalignment reduces maximal oxygen uptake (VO2 max) by approximately 5 to 7% in the first 48 hours after eastward transmeridian travel. [8] Athletes should start the pre-departure protocol 3 days before departure (Day -3) rather than Day -2, and pair NMN/NR with structured light therapy (10,000 lux for 30 minutes at destination wake time).

Individuals with Metabolic Syndrome

Insulin resistance blunts NMN's metabolic effect, as the Dollerup et al. Trial suggested. [6] These travelers benefit most from pairing NMN/NR with a structured meal schedule locked to destination mealtimes from Day -1 onward. Time-restricted eating (first meal within 1 hour of destination sunrise) synchronizes peripheral liver and gut clocks independently of the SCN.